Keywords: |
platelet derived growth factor; vasculotropin; cancer chemotherapy; cancer surgery; unclassified drug; clinical trial; cancer risk; multimodality cancer therapy; cancer adjuvant therapy; cancer radiotherapy; research design; methodology; cancer grading; organization and management; platelet derived growth factor receptor; angiogenesis; oncology; sarcoma; radiation oncology; limb tumor; forecasting; short survey; high risk population; fibroblast growth factor; professional standard; professional staff committees; retroperitoneal sarcoma; humans; human; priority journal; article; 3 [(4,5 dimethyl 1h pyrrol 2 yl)methylene] 1,3 dihydro 2h indol 2 one; beta fibroblast growth factor
|